Apnea of prematurity (AOP) is a significant clinical problem manifested by an unstable respiratory rhythm reflecting the immaturity of respiratory control systems. This review will address the pathogenesis of and treatment strategies for AOP. Although the neuronal mechanisms leading to apnea are still not well understood, recent decades have provided better insight into the generation of the respiratory rhythm and its modulation in the neonate. Ventilatory responses to hypoxia and hypercarbia are impaired and inhibitory reflexes are exaggerated in the neonate. These unique vulnerabilities predispose the neonate to the development of apnea. Treatment strategies attempt to stabilize the respiratory rhythm. Caffeine remains the primary pharmacological treatment modality and is presumed to work through blockade of adenosine receptors A 1 and A 2 . Recent evidences suggest that A 2A receptors may have a greater role than previously thought. AOP typically resolves with maturation suggesting increased myelination of the brainstem.
Apnea of prematurity (AOP) is a manifestation of an unstable respiratory rhythm, reflecting the immaturity of the respiratory control system. Anatomically the immaturity is manifested as decreased synaptic connections, decreased dendritic arborization and poor myelination. As AOP resolves with maturation, it should be considered a developmental disorder rather than a disease state.
Significant advances in our understanding of neonatal respiratory rhythm generation have been made during the last few decades from studies in human and animal neonates. 1 Intracellular recordings and brain slice preparations under reduced experimental conditions have provided important insights. During the late gestational and early neonatal stages, the medullary compartments in the pre-Bötzinger complex and parafacial respiratory group are believed to be responsible for rhythmogenisis. This rhythm is modulated by afferent inputs and is the result of integration of inputs from peripheral and central chemoreceptors, airway afferents and state-dependent controls. Integration of overlapping, opposing synaptic inputs to respiratory motoneurons is important in controlling motor outflow. These key variables and their relevance to the pathogenesis of AOP are discussed below.
Central chemoreceptors and impaired hypercapnic ventilatory response
In response to increasing CO 2 , both adults and term neonates increase their ventilation by increasing tidal volume and breathing frequency, whereas no increase in breathing frequency is seen in preterm infants. [2] [3] [4] Hypercapnic ventilatory response is primarily mediated by central chemoreceptors. Serotonergic (5-HT) neurons, located in the rostral ventrolateral medulla, are putative central chemoreceptors. There is compelling evidence now that there are multiple additional sites of central chemoreception 5 (see for a review). Ventilatory response to CO 2 is significantly reduced in preterm infants but increases with advancing postnatal age. 6, 7 There is even greater impairment of ventilatory response in preterm infants with apnea. Slope of the CO 2 response curve is shifted to the right in infants with apnea 8 (that is, at the same level of CO 2, minute ventilation is lower in apneic infants when compared with their counterparts without apnea). There are no differences in pulmonary mechanics between these two groups, suggesting a central origin for the observed difference. Unlike adults, CO 2 apneic threshold is close to the baseline PCO 2 in preterm infants. 9 Hypoxia can narrow this difference further through reduced metabolism. Any transient hyperventilation event can easily precipitate apnea in these premature infants by decreasing the PCO 2 below the apneic threshold.
Peripheral chemoreceptors and impaired hypoxic ventilatory response
The carotid body is the main peripheral chemoreceptor. The glomus cells, the primary receptors, release transmitters in response to hypoxia, hypercapnia and acidosis, increasing the afferent discharge of the carotid sinus nerve terminals. Dopamine, acetylcholine and 5 0 -adenosine-triphosphate have been proposed to be the excitatory transmitters in the carotid body. The exact oxygen sensor is not known. O 2 -sensitive K þ channel is a candidate. An alternative site may exist in the mitochondria.
Peripheral chemoreceptors are active only at very low oxygen levels in the fetal life and become essentially silent in the immediate postnatal period because of the sudden increase in PaO 2 from <30 mm Hg to 50 to 70 mm Hg range or higher. Peripheral chemoreceptors undergo a resetting phenomenon postnatally. Once it is reset, carotid chemoreceptor drive is significant at relatively hypoxic level of 50 to 70 mm Hg. These infants can become apneic when their inspired oxygen is increased sufficiently to produce a physiologic denervation of peripheral chemoreceptors. 10, 11 Adults show a sustained increase in ventilation in response to hypoxia. N-methyl D-aspartate glutamate receptors in the nucleus of the solitary tract have a pivotal role in the hypoxic ventilatory response. 12 Preterm infants exhibit a biphasic ventilatory response. 13 There is an initial increase in ventilation for approximately 1 min. Following this period, ventilation decreases. In the group of preterm infants with birth weight <1500 g, there is no initial period of hyperventilation. 14 The decrease in ventilation is more pronounced in rapid eye movement sleep and is primarily because of a decrease in breathing frequency. The characteristic biphasic ventilatory response to hypoxia persists for 4 to 6 weeks in preterm infants. 15 The central respiratory depression because of hypoxia is believed to prolong apnea and delay its recovery.
Attenuation of the ventilatory responsiveness to hypoxia has been documented in humans and animal models exposed to chronic hypoxia. Persistence of the biphasic response and delayed emergence of adult response were seen in rat pups exposed to chronic hypoxia from birth. 16 It is also interesting to note that hyperoxia results in blunting of peripheral chemoreceptor response. 17 Katz-Salamon et al. 18 have documented a reduced peripheral chemoreceptor response in preterm infants with bronchopulmonary dysplasia (BPD). There is also evidence linking carotid chemoreceptor over stimulation to the persistence of AOP. [19] [20] [21] Current evidence suggests that both increased and decreased carotid chemoreceptor activity can predispose the preterm infants to apnea.
Airway afferents and enhanced inhibitory response
Lower airway afferents The vagus nerve is the primary afferent source of the lower airway. Unmyelinated fibers (C-fibers) constitute >90% of the respiratory afferents from the lungs and have been implicated in the bronchoconstrictive and bradycardic responses (associated with apnea or rapid shallow breathing) to right heart injection of capsaicin, a C-fiber stimulant. Pulmonary C-fibers are also stimulated by pulmonary edema. Apnea precipitated by patent ductus arteriosus in preterm infants may have a similar basis. Recent finding that the vannilloid receptor-1 antagonist, capsaizepine, blocks the bronchoconstrictive response to capsaicin has provided definitive evidence that C-fiber afferents mediate this reflex response. 22 Myelinated vagal afferents fall into two groups: slowly and rapidly adapting receptors. Slowly adapting receptors, located in the smooth muscle, have a phasic discharge with inflation. Rapidly adapting (irritant) receptors ramify in the tracheo-bronchial epithelium and mediate cough, reflex broncoconstriction and rapid shallow breathing. 23 Among intubated preterm infants, only 1 of 18 infants <35 weeks consistently showed a mature response to direct bronchial mucosal stimulation. The majority of stimulations resulted in marked slowing of breathing or apnea. 24 What role these vagal afferents have in AOP is yet to be determined.
Upper airway afferents
Afferent feedback originating in the upper airway can alter the motor output on a breath by breath basis. Laryngeal afferents responding to changes in respiratory stimuli such as airflow and transmural pressure have been studied extensively and are classified as pressure, flow or drive receptors on the basis of their primary response characteristics. 25, 26 Flow receptors respond to a decrease in temperature; their phasic inspiratory discharge during room air breathing can be eliminated by breathing warm humidified air. 27 Pressure and drive receptors respond primarily to transmural pressure changes and phasic respiratory muscle activity (respiratory drive), respectively. 28 These mechanoreceptors show some degree of chemosensitivity. On the other hand, some laryngeal afferents have no mechanosensitivity. Afferents mediating the laryngeal chemoreflex are stimulated by water and not saline. 29 Elegant studies by Boggs and Bartlet 29 showed that these endings are indeed responding to the lack of small anions such as chloride. Sensory influences originating from the pulmonary and laryngeal afferents are integrated in the nucleus of the solitary tract neurons and have inhibitory projections to phrenic motor neurons ( Figure 1 ). Some laryngeal fibers monosynaptically synapse on cardiac vagal neurons. 30 This accounts for the simultaneous development of apnea and bradycardia observed during laryngeal afferent stimulation. Similar types of endings have been documented in glossopharyngeal and trigeminal nerves.
Enhanced inhibitory responses
Reflex effects of laryngeal afferent stimulation have been investigated extensively in neonatal animal models. These studies show that apnea and inhibition of breathing commonly ensue. 29, 31 Apnea can be induced in tracheostomized animals by applying negative pressure or airflow to the isolated upper airway 31 or instillation of water into the larynx, 29 indicating that laryngeal afferent input into the brainstem is a potent source of inhibition. The classic definition of laryngeal chemoreflex is the triad of apnea, bradycardia and hypertension elicited by instillation of liquids into the larynx. This airway protective response is typically associated with laryngeal closure and swallowing as well. These reflex effects can be eliminated by nerve section and decreases with increasing postnatal age. 29 Greater reflex effects in the neonatal animals cannot be explained on the basis of greater discharge frequencies of the endings in the newborn; instead, it can only be explained on the basis of greater inhibition on the respiratory neurons in the brainstem.
Evidence supporting a role for upper airway afferents in neonatal apnea in humans has emerged slowly over the years. Johnson and Salisbury 32 provided the early evidence in human neonates. Additional evidence for the laryngeal chemoreflex was provided by Perkett and Vaughan. 33 These investigators documented the occurrence of apnea with water infusion but not following saline infusion. Indirect evidence for the existence of an inhibitory response induced by upper airway negative pressure in human neonates was provided by Milner et al. 34 These investigators documented the development of central apnea during airway occlusions in 10 preterm infants, where as none of the term infants exhibited this response. Direct evidence supporting the inhibitory effect of upper airway negative pressure on inspiration was provided by Thach et al. 35 in tracheostomized human neonates. The above observations clearly indicate that stimulation of laryngeal afferents can induce apnea in human neonates. However, their role in spontaneously occurring AOP is not clear.
In newborns of many species including humans, apnea can be elicited by irritants, odors and water applied to the face or into the nose. This apneic reflex is mediated by the trigeminal nerves and is typically associated with bradycardia and laryngeal closure.
A detailed discussion of this reflex is beyond the scope of this review and the reader is referred elsewhere. 36 Whether this reflex is mediated by cold receptors or mechanoreceptors has not been established.
Sleep
Sleep states influence breathing profoundly. Changes in neuromodulatory inputs originating from the catecholaminergic and serotonergic arousal systems of the brainstem are linked to alterations in respiratory function during the sleep-wake cycle. Activity of serotonin-containing neurons decreases by nearly half during slow-wave sleep and become nearly silent during rapid eye movement sleep via activation of GABAergic inputs. 37 Respiration is typically irregular in active sleep, whereas it can be regular or irregular in quiet sleep. Generalized inhibition of skeletal muscle activity seen during active sleep is not observed in the phasic diaphragmatic activity. On the contrary, loss of phasic and tonic activity of pharyngeal muscles such as the genioglossus makes the upper airway uniquely vulnerable for collapse, especially in preterm infants. 38 Furthermore, the overall gain of the respiratory system is decreased during sleep as reflected in the decreased slope of the ventilatory response to CO 2 .
Insights from transgenic models Genetic and environmental factors may lead to severe respiratory problems including apnea. The genetic cause of Congenital Central Hypoventilation Syndrome, defined by the lack of CO 2 responsiveness during sleep, is the mutation of the developmental transcription factor Phox2B. 39 Severe depletion of neurons of the retrotrapezoïd nucleus/parafacial respiratory group was observed in these mice; no other neuronal loss was identified. 40 The Rett syndrome, a neurodevelopmental disorder, is caused by mutations in the transcriptional repressor methyl-CpG-binding protein 2 and is accompanied by complex symptoms, including erratic breathing and life-threatening apneas. 41 Prader-Willi syndrome is caused by the loss of paternal expression of genes in the 15q11-q13 region. Breathing disorders such as apnea, hypoventilation and blunted response to changes in CO 2 or O 2 may be observed from birth. Respiratory defects similar to those seen in Pradder-Willi syndrome have been shown in vivo and in vitro in Necdindeficient mice. 42 These defects are central and are associated with biochemical and anatomical abnormalities of the respiratory control systems.
Neonatal apnea Definition and classification
American Academy of Pediatrics 43 defined AOP as 'cessation of breathing that lasts for at least 20 seconds y.' However, all apneic episodes are not associated with cessation of breathing; some occur in the presence of breathing efforts but are associated with airway obstruction and cessation of airflow. On the basis of respiratory efforts and airflow apnea has been classified as central, obstructive or mixed. Mixed apnea constitutes the majority of apneic episodes. 44 The primary site of airway obstruction appears to be the pharynx, 45 which is the most collapsible portion of the upper airway. A neuromuscular mechanism is necessary to maintain airway patency during life. 46, 47 In the absence of muscle activity, pharyngeal airway in the neonate (with the head in the neutral position) becomes occluded at transmural pressures seen during tidal breathing. 48 This finding is consistent with the observation made by Safar et al. 49 several decades ago. These investigators noted that the pharyngeal airway can become obstructed during induction of anesthesia when pharyngeal muscle activity is depressed. Neck flexion can also precipitate airway obstruction in the neonates. 50 Apnea occurs predominantly during active sleep. 51 Activities of upper airway muscles are reduced markedly during sleep predisposing the upper airway to collapse, especially during inspiration when the upper airway is subjected to airway collapsing forces. Milner et al., 52 utilizing the cardiac oscillation normally present on airflow channel, documented that the airway can become occluded even during central apnea. Further evidence confirming that inspiratory efforts are not essential in the development of upper airway obstruction was provided by Rigatto et al. 53 Lack of upper airway muscle tone during the cessation of central respiratory drive is presumably responsible for this phenomenon.
Relationship to periodic breathing Periodic breathing occurs predominantly during active sleep. Although relatively infrequent during the first few days of life, it becomes more prominent during the first month. Its prevalence approaches 100% in preterm infants weighing <1000 g. 54 In very low birth weight infants, periodic breathing is associated with a significant decrease in minute ventilation and is accompanied by a marked decrease in oxygen saturation. 54 In fact, periodic breathing is a marker for AOP. Rigatto et al. 55 showed that prolonged apnea almost always was preceded by short apneic pauses such as observed during periodic breathing.
Relationship to bradycardia
The triad of apnea, bradycardia and oxygen desaturation occurs frequently in neonatal intensive care units. Air flow is not routinely monitored clinically. Impedance technique utilized for monitoring breathing does not allow the identification of obstructive and mixed apnea. The relationship between apnea, bradycardia and oxygen desaturation has been the focus of numerous clinical studies. Arterial oxygen tension in preterm infants is typically maintained in the 50 to 80 mm Hg range. Given the slope of the oxygen dissociation curve in this range, any significant decrease in ventilation because of apnea quickly results in oxygen desaturation and subsequent bradycardia ( Figure 2 ). It is also clear that during some of apnea and bradycardia episodes, especially in very immature infants, bradycardia precedes oxygen desaturation. Mechanism of development of bradycardia has been subject of debate among various investigators. [56] [57] [58] Carbone et al. 59 reported that apnea and drop in heart rate began simultaneously in 14% of medium and 25% of short apneas. Simultaneous development of apnea and bradycardia can be attributed to enhanced inhibitory responses to airway afferent stimulation. Anatomical and physiological basis for this hypothesis has been compelling in studies utilizing the animal model. Potential relationships between apnea, bradycardia and oxygen desaturation is schematically shown in Figure 2 .
Along with others, we have documented the sudden onset of bradyarrhythmias in very low birth weight infants 60, 61 and most of these bradyarrhythmias develop before oxygen saturation decreases significantly. 61 Non-sinus atrial rhythm (atrial escape) was the most frequent bradyarrhythmia; this was followed by junctional escape and very rarely ventricular escape. 60 This hierarchical response is consistent with increasing vagal tone.
Relationship to gastroesophageal reflux (GER)
Both GER and apnea are common in very low birth weight infants. GER has been implicated as a cause of apnea in premature infants for decades. Yet, there has been no compelling evidence Figure 2 Probable mechanisms involved in the pathogenesis of apnea of prematurity. Potential relationships between apnea, bradycardia and oxygen desaturation are schematically shown. The most common sequence is shown with filled arrows (modified from reference Mathew 56 ).
supporting a causal relationship between the two. On the contrary, some well-designed studies have shown no temporal relationship between GER and apnea. 62 A decrease in lower esophageal sphincter tone and increased GER following apnea has been documented. 63 It is important to remember that airway protective reflexes are elicited when refluxate reaches the laryngeal/ epilaryngeal area and this response includes apnea, laryngeal closure and swallowing. Fortunately, this is a rare event in most infants with GER. Results of a masked trial comparing metoclopramide and ranitidine with saline placebo in a group of preterm infants (each infant serving as his/her own control) in whom the incidence of bradycardia attributed to clinically suspected GER were reported recently. 64 These results have again reaffirmed the available evidence that anti-reflux medications do not reduce bradycardia episodes in preterm infants with GER.
Apnea termination
Arousal is an integral part of termination of sleep apnea in adults. Peripheral chemoreceptors are presumed to mediate this response. We evaluated the role of behavioral arousal in preterm infants with apnea. 65 Behavioral arousal was observed in only a minority of episodes (<10%). However, it was more common in prolonged apnea (>15 s) compared with short apnea and during mixed apnea compared with central apnea. Also, it was more common during apneic episodes with oxygen desaturation <80%. These findings are in agreement with the observations in animal models that several factors such as hypoxia, sleep states and airway afferents have a role in arousal responses. As electroencephalogram (EEG) recordings were not performed as a part of this study, EEG arousal could not be excluded. The relationship between apnea termination and EEG arousal in preterm infants was investigated in a subsequent study by Wulbrand et al. 66 These investigators studied 10 preterm infants longitudinally and observed no EEG changes at apnea termination. McNamara et al. 67 observed EEG changes indicative of cortical arousal in only <10% of apneic events among term infants studied at a mean age of 9.5 weeks. The lack of correlation between oxygen saturation and arousal indicates that peripheral chemoreceptor input does not have a critical role in terminating apnea in these infants. The relative insensitivity of surface EEG to detect subcortical arousal in infants is one explanation. A likely explanation, at least for obstructive apnea, is an increase in neuromuscular drive overcoming airway closure before the onset of arousal. 67 Local neural reflexes that augment the activity of upper airway muscle may have a role in this. Finally, the apneic event could be the result of central respiratory control instability and as such the duration of each event may be predetermined.
Treatment strategies
Periodic breathing with episodic apnea in premature infants is the epitome of unstable rhythm. Treatment strategies for AOP should be based on modulating this unstable respiratory rhythm into a more stable one. Methylxanthines have become the mainstay in the treatment of AOP. A number of non-pharmacological therapies have been attempted over the last few decades. Continuous positive airway pressure (CPAP) has achieved the most success in this arena of non-pharmacological therapies. For a comprehensive review of this topic, the reader is referred elsewhere. 68 Methyl xanthines and central stimulation Methyl xanthines have remained as the primary treatment choice for AOP for three decades 69 (see for a review). They are central stimulants and increase respiratory output. Their effect is not mediated through sleep state changes, at least in neurologically normal and clinically stable preterm infants. 70 Multiple clinical trials have shown that both caffeine and theophylline are effective treatment for AOP. [71] [72] [73] [74] Initially theophylline was the standard therapy and it required close monitoring of serum levels. Since Food and Drug Administration approval of caffeine, theophylline has been largely replaced by caffeine as the first line of management. Methylxanthines increase minute ventilation, improve CO 2 sensitivity, decrease hypoxic depression, enhance diaphragmatic activity and decrease periodic breathing. The common side effects include tachycardia, feeding intolerance, emesis, jitteriness, restlessness and irritability. Toxic levels may produce cardiac dysrhythmias and seizures. Methyl xanthines increase metabolic rate and oxygen consumption. They also have a mild diuretic effect. Caffeine has much less side effects, is better tolerated and has a higher therapeutic index compared with theophylline. Its long half-life translates into convenient once a day dosing regimen and its large margin of safety means monitoring of caffeine levels at the recommended dosing is seldom necessary.
Methylxanthines also increase cerebral metabolic rate 75 and decrease cerebral blood flow. [76] [77] [78] As a result of these findings there were concerns about the long-term effects of caffeine on brain development. However, results of placebo-controlled multicenter trials showed that caffeine therapy for AOP reduces the incidence of bronchopulmonary dysplasia 79 and improves survival without neurodevelopmental disability in very low birth weight infants. 80 In this regard, the finding of Back et al. 81 that caffeine has a protective effect on chronic hypoxia-induced white matter injury is intriguing.
How methyl xanthines stabilize the respiratory rhythm and decrease apnea is not entirely clear. Enhancing the CO 2 sensitivity may be an important component of its effectiveness. Animal studies show that adenosine protects brain cells during experimental hypoxic ischemic episodes. 82, 83 Methylxanthines are inhibitors of adenosine receptors. Although both A 1 and A 2 receptors are involved, a greater role for A 2A receptors has recently emerged. Mechanism of action of methylxanthines in reducing apnea may be through blockade of A 2A receptors on GABAergic neurons. 84 Co-localization of A 2A receptors on GABAergic neurons in the medulla 85 has strengthened this argument.
Doxapram and peripheral chemoreceptors
Doxapram acts as a nonspecific stimulant on the central nervous system. It has a direct effect on medullary respiratory neuron in large doses. However, much smaller doses are used in the treatment of apnea in preterm infants. In these smaller doses doxapram increases tidal volume and minute ventilation in the newborn. 86 These effects are mediated through stimulation of peripheral chemoreceptors because denervation of peripheral chemoreceptors eliminated the increase in ventilation by doxapram at doses <6 mg kg -1 (Mitchell and Herbert 87 ). Several studies have shown the effectiveness of doxapram in reducing apnea refractory to methylxanthines. 86, 88 In a blinded, placebo-controlled trial Peliowski et al. 89 found no significant difference between theophylline and doxapram. As a result of its poor absorption, it is typically used as a continuous intravenous infusion. A number of side effects have been reported with its use. These include increase in blood pressure, abdominal distension, irritability, jitteriness, increased gastric residuals and emesis. Concern about benzyl alcohol, a preservative used in doxapram, has limited its use in the United States.
CPAP and airway patency
Nasal CPAP is effective in reducing apnea in preterm infants. 90 This is especially true when these episodes have an element of airway obstruction but it is not effective in central apnea. 91 This is the basis to suggest that the primary effect of CPAP is on airway patency or its splinting effect. However, CPAP has other effects as well. For example, it has an effect on functional residual capacity. During active sleep, functional residual capacity decreases because of a reduction in tonic and post-inspiratory activity of the diaphragm. 92, 93 CPAP can have a beneficial effect on apnea by increasing the function residual capacity resulting in better oxygenation. By improving oxygenation, CPAP can decrease periodic breathing and apnea. Another potential mechanism is through laryngeal mechanoreceptors. During upper airway positive pressure application, inhibitory feedback from mechanoreceptors in the upper airway is reduced. 94 This decrease in inhibitory influence may translate into more stable respiratory rhythm and less apnea.
Other therapies
Flow through the nasal cannula (both high and low) can be a useful adjunctive therapy in some infants with apnea who are already receiving methylxanthines. High flow produces a distending pressure, especially in the very low birth weight infants. The magnitude of this distending pressure depends on factors such as the flow rate, nasal leak and mouth closure. 95 We do not often monitor the airway pressure while using high flow. Benefits comparable to CPAP have been reported with this form of therapy. 96 It is more intriguing to explain the effects of room air low flow. A neural mechanism is likely. The nose and the larynx are densely innervated and contain both mechanoreceptors and cold receptors. The cold receptors are rapidly adapting and are not stimulated by warm humidified air. Therefore, mechanoreceptors are more likely to mediate this response. The site of origin of this response could be nasal or laryngeal. One could test these hypotheses in well designed studies using local anesthesia. Conventional mechanical ventilation has been the backup option for infants who have significant apnea and bradycardia on methylxanthines and nasal CPAP. In recent years, other less invasive therapies, such as high flow nasal cannula, and nasal intermittent positive pressure ventilation (both synchronized and non-synchronized) have been attempted to avoid endotracheal intubation and mechanical ventilation in these infants to reduce the incidence of bronchopulmonary dysplasia. These therapies have been successful in some infants. Given the high respiratory rate and short inspiratory time as well as the sensitivity and response time of the triggers used, it is difficult to achieve optimal synchronization in the preterm neonate. There is insufficient evidence to suggest that synchronized nasal ventilation is superior to non-synchronized nasal ventilation. On the basis of evidence from the animal model one could make an argument that synchronized phasic afferent input from the upper airway would have a stabilizing influence on respiratory rhythm.
Novel/intriguing therapies Olfactory stimulation. A novel therapy in the form of olfactory stimulation in premature infants with apnea and bradycardia was reported by Marlier et al. 97 They investigated the effects of a pleasant odor in preterm infants with apnea and bradycardia that were refractory to caffeine and doxapram. Introduction of a pleasant odor into the incubator reduced the incidence of apnea and bradycardia significantly in this group of preterm infants. It is worth remembering that only a small group of infants were evaluated and that the treatment effects were evaluated only for 24 h. Apparent lack of side effects is encouraging. A large trial investigating the effectiveness for a longer period of treatment is warranted.
Inhaled CO 2 . Al-Saif et al. 98 evaluated the treatment with low inhaled CO 2 in preterm infants with apnea compared with methylxanthines. These investigators concluded that these two treatment modalities were similarly effective. Inhaled CO 2 reduces apnea largely by regularizing breathing. It decreases the amount of periodic breathing. Furthermore, inhaled CO 2 treatment was not associated with any apparent adverse side effects. This is an intriguing observation from a physiological perspective but is not ready for clinical use.
Exogenous stochastic stimulation. Low-level exogenous stochastic stimulation in stabilizing breathing pattern of preterm infants was tested in a recent study. 99 Mechanosensory stimulation was achieved using actuators embedded within the infant's mattress. The stimulus intensities were subthreshold for causing behavioral arousal or for causing shifts in the power spectrum of EEG activities. An improvement in breathing stability associated with decreased incidence of apneic pauses and a reduction in O 2 destauration was observed. The investigators speculate that the effective stimulus was predominantly somatic mechanoreceptors. This report should be viewed in the historical context in which several attempts at nonspecific afferent stimulation (cutaneous/ muscle/joint/vestibular receptors) have resulted in only transient beneficial effects. 68 A larger study evaluating the long-term benefits is indeed needed.
Maturational effects AOP resolves with maturation. In the vast majority of infants, this occurs around 36 weeks postmenstrual age and are symptom free at discharge. This often coincides with other signs of brainstem maturation, such as suck-swallow co-ordination associated with nipple feeding. In the Collaborative Home Infant Monitoring Evaluation (CHIME) study, the symptomatic group of preterm infants at 42 to 45 weeks postconceptional age and thereafter had events similar to term controls. 100 Physiological basis for the resolution of apnea is believed to be myelination of the brainstem. Evidence supporting this notion was provided by an elegant study by Henderson-Smart et al.
101
Utilizing auditory evoked responses, these investigators studied a group of babies with and without apnea and showed that brainstem conduction time was shorter in infants without apnea when compared to preterm infants with apnea. Furthermore, when infants with apnea were longitudinally followed, the time of resolution apnea coincided with shortening of conduction time, suggesting the onset of myelination of this pathway. Further indirect supporting evidence was provided by the observation by Eichenwald et al. 102 that AOP persists well beyond term gestation in the most immature preterm infants (24 to 28 weeks). Delayed postnatal myelination of these extremely premature infants is likely to be responsible for this observation. Cortical maturation appear to be preserved after moderate prematurity, 103 whereas high incidence of white mater injury was seen in extremely premature infants at term equivalent age 104 and was associated with neurodevelopmental delay. Cerebral palsy and developmental delay are associated with delay in myelination of cerebral white mater.
